Bill to pay for multi-cancer early detection screening test has bipartisan support, but just ran out of time last session.

The U.S. Department of Health & Human Services may seek over $1 billion from Johnson & Johnson as reimbursement for federal ...

Guardant Health, Inc. (NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the ...

Insurers rejected one-third of new prescriptions for specialty oral anticancer medications ordered for patients with blood ...

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with ...

The cost of cancer may be higher than previously estimated, according to a recent report from the American Cancer Society.

Given forthcoming changes to Medicare Part D plans under the Inflation Reduction Act, CMS should collect and publish ...

This test predicts cancer recurrence ... This represents an expansion from the prior Medicare coverage of Guardant Reveal testing for CRC only in the early post-surgical setting.

Five cancer drugs − Revlimid, Pomalyst, Imbruvica, Jakafi, and Ibrance − cost Medicare enrollees $11,000 to nearly $15,000 per drug in 2023, according to a KFF analysis. What's more ...

Medicare covers inpatient and outpatient care for skin cancer. People with Original Medicare parts A and B or Medicare Advantage plans can expect extensive coverage, but they will likely have out ...